Biosurgery Market Size, Share, Growth, Trends, and Global Industry Analysis: By Resin Type (Haemostatic Agents, Surgical Sealants and Adhesives, Adhesion Barriers, Soft Tissue Attachments, Bone-Graft Substitutes, Staple-Line Reinforcement Materials, Others, By Application (General Surgery, Orthopedic Surgery, Cardiovascular Surgery, Neurosurgery, Gynecological Surgery, Urological Surgery, Reconstructive Surgery, Others), By End User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Others) and Region Forecast 2020-2031

Biosurgery Market size was valued at US$ 14,752.9 million in 2024 and is projected to reach US$ 23,381.7 million by 2031 at a CAGR of 6.8% from 2025-2031. Moreover, the U.S Biosurgery Market is projected to grow at a CAGR of 6.7% CAGR over the forecast period.

The market refers to the segment of healthcare that encompasses advanced surgical products and techniques designed to support surgical procedures by minimizing blood loss, enhancing wound healing, reducing complications, and improving recovery outcomes. It includes a wide range of biologically and synthetically derived products such as hemostatic agents, surgical sealants, adhesion barriers, and soft tissue repair materials used across multiple specialties including Orthopedic, cardiovascular, neurosurgery, and general surgery.

The market is witnessing steady growth driven by the rising volume of surgical procedures, advancements in biomaterials, and increasing demand for minimally invasive techniques. With a growing prevalence of chronic conditions such as cardiovascular diseases, cancer, and obesity-related complications, the need for efficient surgical interventions is expanding globally. Moreover, the market benefits from technological innovations that improve product safety and efficacy, alongside favorable reimbursement structures in developed regions.

Facts & Figures

• In fact, Hemostatic agents account for over 30% of total biosurgery product usage globally.
• Orthopedic surgeries represent approximately 25%–28% of all biosurgery applications.
• Hospitals utilize more than 70% of biosurgery products compared to ambulatory surgical centers and specialty clinics.
• The average surgical sealant reduces intraoperative blood loss by 15%–20% per procedure.
• Adhesion barriers are used in over 40% of abdominal and pelvic surgeries to prevent post-operative adhesions.

Key Developments

• In September 2024, HCAH, a leading provider of out-of-hospital healthcare solutions in India, has launched a new initiative aimed at improving patient recovery through advanced wound care. The program is established in partnership with Aroa Biosurgery, a New Zealand-based company specializing in medical and surgical products for soft tissue regeneration and complex wound management.
• In May 2024, Johnson & Johnson received a CE mark in November for Ethizia, a hemostatic sealing patch designed to control bleeding in internal organs. Although the product has not yet received approval from the U.S. Food and Drug Administration, it is expected to strengthen J&J’s biosurgery segment, contributing to the expansion of its medtech portfolio. Ethizia’s introduction highlights the company’s focus on innovative surgical solutions that improve hemostasis, enhance patient outcomes, and support the growing demand for advanced biosurgical products in global healthcare markets.

Biosurgery Market Segmentation

Based on the product type

• Hemostatic Agents
• Surgical Sealants and Adhesives
• Adhesion Barriers
• Soft Tissue Attachments
• Bone-Graft Substitutes
• Staple-Line Reinforcement Materials
• Others

Among the product types, hemostatic agents are anticipated to lead the biosurgery market due to their critical role in managing blood loss during surgical procedures. Rising surgical volumes, particularly in cardiovascular, orthopedic, and trauma surgeries, have intensified the demand for effective hemostatic solutions that ensure rapid clotting and minimize complications. Surgeons prefer advanced hemostatic agents because they enhance surgical efficiency, reduce operative time, and improve patient recovery outcomes. Furthermore, the increasing adoption of minimally invasive surgeries, where precise bleeding control is essential, further drives their usage. Supported by continuous product innovations, hemostatic agents are expected to maintain market leadership.

Based on the application

• General Surgery
• Orthopedic Surgery
• Cardiovascular Surgery
• Neurosurgery
• Gynecological Surgery
• Urological Surgery
• Reconstructive Surgery
• Others

Among the applications, orthopedic surgery is anticipated to account for the largest share of the biosurgery market, driven by the rising incidence of bone-related disorders, fractures, and joint replacement procedures. With the global aging population and increasing prevalence of conditions such as osteoporosis and arthritis, the demand for orthopedic interventions is surging. Biosurgical products such as bone-graft substitutes, soft tissue repair materials, and hemostatic agents play a vital role in ensuring surgical success, faster healing, and reduced post-operative complications in orthopedic care. Moreover, the trend toward minimally invasive orthopedic procedures, coupled with growing adoption of advanced biomaterials, strongly supports market growth in this segment.

Based on the end user

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Others

Among end users, hospitals are anticipated to dominate the biosurgery market due to their high surgical volumes, advanced infrastructure, and capacity to adopt a wide range of biosurgical products. Hospitals perform complex procedures across multiple specialties, including cardiovascular, orthopedic, and neurosurgeries, where the use of hemostatic agents, surgical sealants, and adhesion barriers is critical to improving patient outcomes. Additionally, hospitals often have established procurement processes and favorable reimbursement mechanisms, enabling the consistent adoption of premium biosurgery solutions. The increasing focus on reducing operative time, minimizing complications, and enhancing post-operative recovery further reinforces hospitals as the leading end-user segment.